Markets & Regulations

Five biggest CDMO deals of the year

Five deals reshaping the CDMO industry this year

By Ben Hargreaves

The major trend so far in 2019 is the willingness to deploy capital to expand services in the cell and gene therapy sector, and we outline the five most significant deals thus far.

Valneva-GSK sever vaccine alliance

GSK-Valneva end legacy vaccines partnership

By Ben Hargreaves

GSK and Valneva have come to a mutual early termination agreement, as the former looks to ‘allocate capital to fewer, highest priority areas’.

Follow us

Products

View more

Webinars